▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #815 by analyst upside · 2026-08-12
SLDB
Solid Biosciences Inc.
Healthcare · Market Cap $949M · P/E 0x
ANALYST PRICE TARGET
+99.3%
implied upside to consensus target
Current Price $8.85
Consensus Target $17.64
Bull Target $26.0
Bear Target $11.0
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
7
Hold
0
Sell
0
52-Week Low $3.79
52-Week High $11.45
YTD Return +62.4%
FUNDAMENTALS
Market Cap $949M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.89
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.79
52-Week High $11.45
Current Price $8.85
Bear Target $11.0
Bull Target $26.0
● Now $8.85 ● Target $17.64
TRADING DATA
Avg Volume 1.7M
YTD Return +62.4%
Analyst Count 11
Consensus Buy
Upside to Target +99.3%
Last Updated 2026-08-12

ANALYST SUMMARY

Solid Biosciences Inc. (SLDB) is currently trading at $8.85 with a Wall Street consensus price target of $17.64, implying potential upside of 99.3% over the next 12 months. 11 analysts currently cover SLDB, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $26.0, while the most cautious has a target of $11.0.

SLDB operates in the Healthcare sector with a market capitalisation of $949M. The stock is up 62.4% year-to-date and is currently trading near the upper end of its 52-week range of $3.79 – $11.45.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

COLL +97.1%
Collegium Pharmaceutical, Inc.
$843M · P/E 20.5x · Buy
ZVRA +120.5%
Zevra Therapeutics, Inc.
$673M · P/E 12.2x · Buy
NUTX +60.0%
Nutex Health Inc.
$1B · P/E 6.5x · Buy
CRMD +105.5%
CorMedix Inc.
$573M · P/E 3.4x · Strong Buy
OMER +142.6%
Omeros Corporation
$984M · P/E 11.9x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for SLDB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. - Reiterated
Buy → Buy 2026-06-03 31% win rate (48 calls)
Wedbush reit
Outperform → Outperform 2026-05-18 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-05-13 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-05-13 14% win rate (7 calls)
JP Morgan - Reiterated
Overweight → Overweight 2026-03-25 43% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-03-23 31% win rate (48 calls)
Guggenheim ● Initiated
Buy 2026-03-20 62% win rate (8 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-03-20 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
46
out of 100
Coverage depth
19/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →